Biography
Adam Schoen is a partner and co-practice group leader of Brown Rudnick's Global Intellectual Property Practice Group and Global Life Sciences Group. Adam has been in the life sciences industry for over 20 years and has over 15 years of experience advising life sciences and medical device funds, companies, and academic institutions. Adam helps his clients build, grow, invest in, buy, and sell companies of all sizes all over the world. Adam’s practice is multidisciplinary, encompassing all aspects of patent preparation and prosecution, portfolio development, product clearance, freedom to operate analysis, intellectual property due diligence, licensing, and other agreement work.
Adam has experience developing and implementing worldwide patent strategies across the life sciences industry. He works with a variety of technologies, such as small molecule therapeutics, biologics (including gene therapies and immunotherapeutics), gene editing technology, next generation sequencing technologies, microfluidics and droplet based technologies, diagnostics (including cancer and fertility diagnostics), medical device technology (ophthalmology, cardiology, orthopedics, otolaryngology, neurology, and spine), medical imaging technology (ultrasound and OCT), mass spectrometry, and digital health products.
Prior to law school, Adam was a scientist of analytical chemistry for ArQule, a combinatorial chemistry and drug discovery company, and a scientist at Millennium Pharmaceuticals.
Work Highlights
Providing Strategic IP Transactional Advice
- Multiple east coast, west coast, and European venture funds and their portfolio companies, as IP counsel for investment transactions in the small molecule therapeutics, biologics (including gene therapies and immunotherapeutics), medical devices, and diagnostic spaces.
- Latigo Biotherapeutics, a clinical-stage biotechnology company developing novel and non-opioid therapies for chronic pain, in multiple matters, including:
- as IP counsel in its $150 million Series B financing.
- as IP counsel in its $135 million Series A financing.
- Climb Bio, a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, as IP counsel to company and deal team for exclusive license agreement with Beijing Mabworks Biotech.
- Kate Therapeutics, a biotech startup focused on treating debilitating muscle disorders, in multiple matters, including:
- as IP counsel in its $1.1 billion sale to Novartis.
- its licensing deal with Astellas Pharma to develop and commercialize a gene therapy for a debilitating muscle disorder.
- Aliada Therapeutics, a biotech company, in multiple matters, including:
- as IP counsel for day-to-day IP matters and member of team for sale of business to AbbVie.
- in a co-development agreement with Chiesi Global Rare Diseases to develop a novel blood-brain barrier-crossing platform technology in lysosomal storage disorders.
- Navigator Medicines, a New Jersey-based biotech startup, as IP counsel following its $100 million Series A financing round.
- Latus Bio, a biotech startup that aims to develop novel gene therapy candidates for central nervous system disorders.
- Acelyrin, an immunology-focused drug developer, as IP counsel in its $540 million initial public offering.
- Capsida in a collaboration deal with Prevail, a subsidiary of Eli Lilly.
- Tmunity in its acquisition by Kite/Gilead.
- Capsida in its collaboration deal with Abbvie.
- Aerovate in its IPO.
- Immunotherapeutics company in its collaboration with a leading pharmaceutical company.
- West coast venture fund in a joint venture with a German small molecule therapeutics company to develop a suite of neurology small molecule assets.
- Preclinical digital pathology company in a collaboration agreement with a premier contract research organization for clinical and non-clinical services.
- U.S. university in the microfluidics space that was licensed to a diagnostics company.
Developing Patent Portfolios
- Emerging company with a small molecule cancer asset in clinical trials.
- Emerging company with a small molecule asset for heart disease in clinical trials and have led company through multiple rounds of diligence with investors.
- U.S. university with over 200 patents worldwide covering various mass spectrometry technologies that have been licensed to leading analytical instrument companies and other emerging companies.
- Medical device company with a product to treat acute decompensated heart failure; multiple investor diligences.
- Clinical-stage biotechnology company focusing on personalized cellular immunotherapy; multiple investor diligences. The product is in clinical trials.
- Tools company in immunotherapeutics in a commercial supply agreement with a leading material science and life science products company, and subsequent sale to a clinical stage immunotherapy company; continued IP representation after the sale.
- Diagnostic company with cell technology and machine learning models that characterize the immune system that drove sale of company to diagnostic company in the immunotherapy space.
- Irish medtech company with device for treating nasal disorders that has driven multiple successful rounds of investment.
- Emerging British company developing safe and effective drug delivery systems for cell and gene therapeutics and have led the company through multiple investor diligences.
- Emerging company with next generation cell therapy technology for treatment of solid tumors and have led the company through multiple investor diligences.
- Emerging company for a suite of specialized tools for minimally invasive orthopedic procedures and have led the company through multiple investor diligences.
- Therapeutics company with a small molecule asset for certain neuropsychiatric and neurological disorders.
- Immunotherapy company with an asset for cancer treatment.
- Gene therapy company developing assets for treating neurological disorders.
- Therapeutics company with a small molecule asset for certain cancers.
- Israeli medical device company with device for treatment of heart failure.
- Therapeutics company with a small molecule asset for treating neurological disorders.
- Therapeutics company with a biologics asset for treating renal disorders.
- Therapeutics company with a small molecule asset for treating pain disorders.
- Digital health company with diagnostic device and proprietary software platform for assessing male fertility.
- Digital health company with proprietary software platform for virtual surgical simulations.
- Synthetic biology company with proprietary technology for developing cotton in vitro.
- Synthetic biology company with proprietary technology for developing various chemical compounds at scale.
- Digital health company with diagnostic methods and proprietary software platform for care management solution for workers’ injury prevention and recovery.
- Therapeutics company with products for delivery of drugs to the gastrointestinal system.
- Therapeutics company with small molecule asset for treating kidney disorders.
- Digital health company with software platform for modeling delivery of compounds to different tissues.
- Digital health company with software platform for assessing wellness and diagnosing psychiatric disorders.
- Therapeutics company with products for treating inflammatory conditions.
- Gene therapy company developing proprietary vectors for delivering a gene therapy.
- Medical device company developing a product for treating infections.
- Medical device company with proprietary software platform developing a product for assessing and monitoring water quality.
- Medical device company with image guided solutions for minimally invasive procedures.
- Microfluidics company developing microfluidic based immunoassays.
- Medical device company developing bone grafting products.
- Diagnostics company with methods for assessing neurological conditions.
- Medical device company developing an ultrasound-based platform for drug delivery.
- T cell therapy company that was acquired by a neuro-immunology company, with continued IP representation of the company after acquisition.
- Microfluidics and genetic diagnostics company with over 150 patents that was acquired by a biopharmaceutical company for over $75 million, with continued IP representation of the company after acquisition.
- Ablation catheter company to treat atrial fibrillation that was acquired by an Italian medical device company, with continued IP representation of the company after acquisition.
- Sale of numerous small molecule assets to a leading pharmaceutical company, including analysis over 50 patents and licenses and litigation settlement agreements, and negotiating IP aspects of the transaction documents.
- 100 patents for a sequencing company sold to a leading sequencing company.
- 30 patents for a fluidics and molecular diagnostic company sold to large molecular diagnostic company.
- Medical device company with a laparoscopic surgical instrument that was sold to a leader in medical technology.
- 30 patents for a microfluidics company that was acquired by a biopharmaceutical company.
- Large imaging guided therapy company in the ultrasound and OCT space.
- Large healthcare company in the medical records space and the imaging device space.
- U.S. university in the genetic diagnostics space with patent portfolio that was licensed to an emerging diagnostics and therapeutics company.
- Medical device company with product in glaucoma space.
- Digital health company with diagnostic device and proprietary software platform for analyzing blood and diagnosing a disorder.
- Digital health company with diagnostic methods and proprietary software platform for assessing infertility.
- Medtech company with a device for treating neurological disorders.
Education
New England School of Law, J.D., magna cum laude, New England Scholar, Dean's Honor List
Cornell University, B.S.
Bar Admissions
Massachusetts
U.S. Patent and Trademark Office
| News |
| Publications |
| Speaking Engagements |
| Awards and Honors |
| Firm Activities |
© 2025 Brown Rudnick LLP. Attorney Advertising